BioCryst (NASDAQ:BCRX) announced today that it is canceling its merger with Presidio Pharmaceuticals, an event that Motley Fool health care analyst Brenton Flynn predicted could happen last month. With BioCryst's Hep-C candidate impaired, and companies like Abbott (NYSE:ABT) and Gilead (NYSE:GILD) already light-years ahead in the race for an all-oral Hepatitis C regimen, it's easy to understand why a deal for Presidio and its phase-2-ready drug didn't make sense.
